Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006007 · ClinicalTrials.gov registry record · Phase 2
LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer
A Phase 2 study of Breast Cancer, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
- 20
- Study locations
NCT00006007: Completed Phase 2 study of Breast Cancer, sponsored by Alliance for Clinical Trials in Oncology.
NCT00006007 is a Phase 2 study of Breast Cancer that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 59 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006007, a Phase 2 study of Breast Cancer, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining LY231514 plus gemcitabine in treating women who have metastatic breast cancer.
Conditions Studied
Interventions
- DRUG gemcitabine hydrochloride
- DRUG pemetrexed disodium
Study Locations (20)
Minnesota
- CCOP - Duluth - Duluth
- Mayo Clinic Cancer Center - Rochester
- CentraCare Health Plaza - Saint Cloud
- CCOP - Metro-Minnesota - Saint Louis Park
Illinois
- CCOP - Illinois Oncology Research Association - Peoria
- Illinois Oncology Research Association - Peoria
- CCOP - Carle Cancer Center - Urbana
Iowa
- CCOP - Cedar Rapids Oncology Project - Cedar Rapids
- CCOP - Iowa Oncology Research Association - Des Moines
- Siouxland Hematology-Oncology - Sioux City
North Dakota
- Medcenter One Health System - Bismarck
- CCOP - Merit Care Hospital - Fargo
- Altru Health Systems - Grand Forks
Arizona
- CCOP - Scottsdale Oncology Program - Scottsdale
Florida
- Mayo Clinic - Jacksonville
Kansas
- CCOP - Wichita - Wichita
Louisiana
- CCOP - Ochsner - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2000-12 |
| Est. Completion | 2008-05 |
| Phase | Phase 2 |
What the finished NCT00006007 record still lists
NCT00006007 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which gemcitabine hydrochloride is the first listed.
NCT00006007 names 20 study sites across 11 states, led by Minnesota, Illinois, Iowa.
Frequently Asked Questions
What is clinical trial NCT00006007 about?
NCT00006007 is a clinical study titled "LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining LY231514 plus gemcitabine in treating women who have metast...
What is the current status of trial NCT00006007?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2000-12. Estimated completion is 2008-05.
What conditions does trial NCT00006007 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00006007?
The interventions under investigation include: gemcitabine hydrochloride (DRUG), pemetrexed disodium (DRUG).
Who is sponsoring clinical trial NCT00006007?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006007 being conducted?
This trial has 20 study locations across Arizona, Florida, Illinois, Iowa, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00006007's enrollment target sits among peer trials
59 758th of 1224 higher than 465 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia